Bayer and MOMA Therapeutics have announced a new collaboration aimed at advancing precision cancer treatments. The ...
ADCs are at the forefront of cancer treatment, providing targeted therapies with promising results for lung cancer. We have ...
Antibody-drug conjugates (ADCs) represent a significant breakthrough in oncology, offering targeted treatments, for lung ...
Antibody-drug conjugates (ADCs) are transforming the landscape of cancer treatment by targeting hard-to-treat cancers with ...
Oncolytic viruses are emerging as a promising development in cancer treatment. We will have an interview with Dr. Thomas C.
AI can play a crucial role in drug discovery, but the lack of sufficient data in this area remains a significant obstacle. We ...
We welcomed two special guests, Dr. Stacy Lindborg, CEO of IMUNON, and Dr. Premal Thaker, Gynecologic Oncologist at Washington University, to discuss the results of the OVATION 2 Study and the latest ...
The latest data from the Phase III NATALEE trial, presented at ESMO 2024, demonstrate that adding Kisqali (ribociclib) to standard endocrine therapy reduces the risk of breast cancer recurrence by ...
The next-generation weight loss therapeutic, nimacimab, has entered the Phase 2 CBeyond clinical trial. The study aims to determine the safety of nimacimab, focusing on sustainable weight loss and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback